A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

March 20, 2024 updated by: AstraZeneca

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Study Overview

Status

Recruiting

Conditions

Breast Cancer

Intervention / Treatment

Detailed Description

The primary objectives of the study are to demonstrate superiority of Dato-DXd relative to ICC by assessment of PFS in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, per BICR and to demonstrate superiority of Dato-DXd relative to ICC by assessment of OS in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Study Type

Interventional

Enrollment (Estimated)

600

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: AstraZeneca Clinical Study Information Center
Phone Number: 1-877-240-9479
Email: information.center@astrazeneca.com

Study Locations

Argentina
- - Buenos Aires, Argentina, 1058
    - Recruiting
    - Research Site
  - Buenos Aires, Argentina, C1125ABD
    - Recruiting
    - Research Site
  - Caba, Argentina, 1414
    - Recruiting
    - Research Site
  - Caba, Argentina, 1426
    - Recruiting
    - Research Site
  - Ciudad Autónoma Buenos Aires, Argentina, C1430EFA
    - Recruiting
    - Research Site
  - Mar del Plata, Argentina, B7600
    - Recruiting
    - Research Site
  - Rosario, Argentina, 2000
    - Recruiting
    - Research Site
Belgium
- - Anderlecht, Belgium, 1070
    - Recruiting
    - Research Site
  - Brasschaat, Belgium, 2930
    - Withdrawn
    - Research Site
  - Gent, Belgium, 9000
    - Recruiting
    - Research Site
  - Liège, Belgium, 4000
    - Recruiting
    - Research Site
  - Namur, Belgium, 5000
    - Recruiting
    - Research Site
  - Sint-Niklaas, Belgium, 9100
    - Recruiting
    - Research Site
  - Wilrijk, Belgium, 2610
    - Recruiting
    - Research Site
Brazil
- - Brasilia, Brazil, 71681-603
    - Recruiting
    - Research Site
  - Brasília, Brazil, 70200-730
    - Withdrawn
    - Research Site
  - Curitiba, Brazil, 80440-220
    - Recruiting
    - Research Site
  - Goiânia, Brazil, 74000-000
    - Recruiting
    - Research Site
  - Jaú, Brazil, 17210-120
    - Recruiting
    - Research Site
  - Porto Alegre, Brazil, 91350-200
    - Recruiting
    - Research Site
  - Porto Alegre, Brazil, 90619-900
    - Recruiting
    - Research Site
  - Rio de Janeiro, Brazil, 20560-120
    - Recruiting
    - Research Site
  - São Paulo, Brazil, 01321-001
    - Recruiting
    - Research Site
  - São Paulo, Brazil, 01409-001
    - Recruiting
    - Research Site
  - São Paulo, Brazil, 01246-000
    - Recruiting
    - Research Site
Canada
- - Quebec, Canada, G1S 4L8
    - Recruiting
    - Research Site
- Alberta
  - Calgary, Alberta, Canada, T2N 4N2
    - Recruiting
    - Research Site
- Ontario
  - Barrie, Ontario, Canada, L4M 6M2
    - Recruiting
    - Research Site
  - Hamilton, Ontario, Canada, L8V 5C2
    - Recruiting
    - Research Site
  - Ottawa, Ontario, Canada, K1H 8L6
    - Recruiting
    - Research Site
  - Toronto, Ontario, Canada, M5G 2M9
    - Recruiting
    - Research Site
- Quebec
  - Greenfield Park, Quebec, Canada, J4V 2H1
    - Recruiting
    - Research Site
  - Montreal, Quebec, Canada, H4A 3J1
    - Recruiting
    - Research Site
  - Montreal, Quebec, Canada, H3T 1E2
    - Recruiting
    - Research Site
- Saskatchewan
  - Saskatoon, Saskatchewan, Canada, S7N 4H4
    - Recruiting
    - Research Site
China
- - Beijing, China, 100044
    - Active, not recruiting
    - Research Site
  - Beijing, China, 100021
    - Active, not recruiting
    - Research Site
  - Beijing, China, 100039
    - Active, not recruiting
    - Research Site
  - Bengbu, China, 233060
    - Active, not recruiting
    - Research Site
  - Changchun, China, 130021
    - Active, not recruiting
    - Research Site
  - Changsha, China, 410013
    - Active, not recruiting
    - Research Site
  - Changsha, China, 410008
    - Active, not recruiting
    - Research Site
  - Chengdu, China, 610000
    - Active, not recruiting
    - Research Site
  - Chongqing, China, 400016
    - Completed
    - Research Site
  - Guangzhou, China, 510060
    - Active, not recruiting
    - Research Site
  - Guangzhou, China, 510100
    - Active, not recruiting
    - Research Site
  - Hangzhou, China, 310003
    - Active, not recruiting
    - Research Site
  - Hangzhou, China, 310009
    - Active, not recruiting
    - Research Site
  - Hangzhou, China, 310022
    - Completed
    - Research Site
  - Hefei, China, 230601
    - Recruiting
    - Research Site
  - Hefei, China, 230031
    - Active, not recruiting
    - Research Site
  - Jinan, China, 250001
    - Active, not recruiting
    - Research Site
  - Nanchang, China, 330009
    - Active, not recruiting
    - Research Site
  - Nanjing, China, 210029
    - Active, not recruiting
    - Research Site
  - Shandong, China
    - Active, not recruiting
    - Research Site
  - Shanghai, China, 200032
    - Active, not recruiting
    - Research Site
  - Shanghai, China, 200025
    - Active, not recruiting
    - Research Site
  - Shenyang, China, 110042
    - Active, not recruiting
    - Research Site
  - Shenzhen, China, 518029
    - Active, not recruiting
    - Research Site
  - Tianjin, China, 300060
    - Active, not recruiting
    - Research Site
  - Xi'an, China, 710004
    - Active, not recruiting
    - Research Site
  - Xian, China, 710100
    - Active, not recruiting
    - Research Site
  - Zhengzhou, China, 450008
    - Active, not recruiting
    - Research Site
  - Zhengzhou, China
    - Active, not recruiting
    - Research Site
France
- - Bordeaux, France, 33076
    - Recruiting
    - Research Site
  - Dijon, France, 21079
    - Recruiting
    - Research Site
  - Limoges Cedex, France, 87042
    - Recruiting
    - Research Site
  - Lyon, France, 69373
    - Recruiting
    - Research Site
  - Marseille, France, 13273
    - Recruiting
    - Research Site
  - Montpellier, France, 34298
    - Recruiting
    - Research Site
  - Paris, France, 75010
    - Recruiting
    - Research Site
  - Rouen, France, 76021
    - Recruiting
    - Research Site
  - Saint Cloud, France, 92210
    - Withdrawn
    - Research Site
  - Saint Herblain Cedex, France, 44805
    - Recruiting
    - Research Site
  - Tours, France, 37000
    - Recruiting
    - Research Site
Germany
- - Aschaffenburg, Germany, 63739
    - Recruiting
    - Research Site
  - Bonn, Germany, 53111
    - Recruiting
    - Research Site
  - Düsseldorf, Germany, 40479
    - Withdrawn
    - Research Site
  - Frankfurt am Main, Germany, 60431
    - Recruiting
    - Research Site
  - Georgsmarienhuette, Germany, 49124
    - Recruiting
    - Research Site
  - Gerlingen, Germany, 70839
    - Withdrawn
    - Research Site
  - Hamburg, Germany, 20357
    - Withdrawn
    - Research Site
  - Hannover, Germany, 30625
    - Recruiting
    - Research Site
  - Heilbronn, Germany, 74078
    - Recruiting
    - Research Site
  - Koblenz Am Rhein, Germany, 56068
    - Recruiting
    - Research Site
  - Langen, Germany, 63225
    - Recruiting
    - Research Site
  - München, Germany, 81377
    - Recruiting
    - Research Site
  - Münster, Germany, 48149
    - Recruiting
    - Research Site
  - Wiesbaden, Germany, 65199
    - Recruiting
    - Research Site
Hungary
- - Budapest, Hungary, 1122
    - Recruiting
    - Research Site
  - Budapest, Hungary, 1062
    - Recruiting
    - Research Site
  - Győr, Hungary, 9024
    - Recruiting
    - Research Site
  - Miskolc, Hungary, 3526
    - Recruiting
    - Research Site
  - Nyíregyháza, Hungary, 4400
    - Recruiting
    - Research Site
  - Zalaegerszeg, Hungary, 8900
    - Recruiting
    - Research Site
India
- - Bangalore, India, 560004
    - Recruiting
    - Research Site
  - Jaipur, India, 302022
    - Recruiting
    - Research Site
  - Kolkata, India, 700160
    - Recruiting
    - Research Site
  - Nagpur, India, 440001
    - Recruiting
    - Research Site
  - Nashik, India, 422009
    - Recruiting
    - Research Site
  - New Delhi, India, 110085
    - Recruiting
    - Research Site
  - Pondicherry, India, 605006
    - Recruiting
    - Research Site
  - Vadodara, India, 391760
    - Recruiting
    - Research Site
  - Vizag, India, 530040
    - Withdrawn
    - Research Site
Italy
- - Aviano, Italy, 33081
    - Withdrawn
    - Research Site
  - Borgo San Lorenzo, Italy, 50032
    - Recruiting
    - Research Site
  - Catanzaro, Italy, 88100
    - Recruiting
    - Research Site
  - Genova, Italy, 16132
    - Recruiting
    - Research Site
  - Livorno, Italy, 57126
    - Recruiting
    - Research Site
  - Macerata, Italy, 62100
    - Recruiting
    - Research Site
  - Milan, Italy, 20141
    - Recruiting
    - Research Site
  - Milano, Italy, 20132
    - Recruiting
    - Research Site
  - Modena, Italy, 41124
    - Recruiting
    - Research Site
  - Napoli, Italy, 80131
    - Recruiting
    - Research Site
  - Roma, Italy, 00137
    - Recruiting
    - Research Site
  - Rozzano, Italy, 20089
    - Recruiting
    - Research Site
Japan
- - Chuo-ku, Japan, 104-0045
    - Recruiting
    - Research Site
  - Fukushima-shi, Japan, 960-1295
    - Recruiting
    - Research Site
  - Gifu-shi, Japan, 501-1194
    - Recruiting
    - Research Site
  - Hiroshima-shi, Japan, 730-8518
    - Recruiting
    - Research Site
  - Isehara-shi, Japan, 259-1193
    - Recruiting
    - Research Site
  - Kagoshima-shi, Japan, 892-0833
    - Recruiting
    - Research Site
  - Kashiwa, Japan, 277-8577
    - Recruiting
    - Research Site
  - Kitaadachi-gun, Japan, 362-0806
    - Recruiting
    - Research Site
  - Koto-ku, Japan, 135-8550
    - Recruiting
    - Research Site
  - Kyoto-shi, Japan, 606-8507
    - Recruiting
    - Research Site
  - Matsuyama-shi, Japan, 791-0280
    - Recruiting
    - Research Site
  - Nagoya-shi, Japan, 466-8560
    - Recruiting
    - Research Site
  - Nagoya-shi, Japan, 464-8681
    - Recruiting
    - Research Site
  - Nagoya-shi, Japan, 467-8602
    - Recruiting
    - Research Site
  - Niigata-shi, Japan, 951-8566
    - Recruiting
    - Research Site
  - Nishinomiya-shi, Japan, 663-8501
    - Recruiting
    - Research Site
  - Sendai-shi, Japan, 980-8574
    - Recruiting
    - Research Site
  - Shinagawa-ku, Japan, 142-8666
    - Recruiting
    - Research Site
  - Shinjuku-ku, Japan, 162-8655
    - Recruiting
    - Research Site
  - Tsu-shi, Japan, 514-8507
    - Recruiting
    - Research Site
  - Tsukuba, Japan, 305-8577
    - Recruiting
    - Research Site
  - Yokohama-shi, Japan, 241-8515
    - Recruiting
    - Research Site
Korea, Republic of
- - Busan-si, Korea, Republic of, 602-739
    - Recruiting
    - Research Site
  - Daegu, Korea, Republic of, 41404
    - Recruiting
    - Research Site
  - Goyang-si, Korea, Republic of, 10408
    - Withdrawn
    - Research Site
  - Seoul, Korea, Republic of, 03722
    - Recruiting
    - Research Site
  - Seoul, Korea, Republic of, 05505
    - Recruiting
    - Research Site
  - Seoul, Korea, Republic of, 06351
    - Recruiting
    - Research Site
  - Seoul, Korea, Republic of, 03080
    - Recruiting
    - Research Site
  - Seoul, Korea, Republic of, 06273
    - Recruiting
    - Research Site
Mexico
- - CD Mexico, Mexico, 04980
    - Recruiting
    - Research Site
  - Guadalajara, Mexico, 44670
    - Recruiting
    - Research Site
  - Guadalajara Jalisco, Mexico, 44280
    - Recruiting
    - Research Site
  - Mexico, Mexico, 14080
    - Recruiting
    - Research Site
  - Mexico, Mexico, 6760
    - Recruiting
    - Research Site
  - Mexico City, Mexico, 0 3100
    - Recruiting
    - Research Site
Philippines
- - Bacolod, Philippines, 6100
    - Recruiting
    - Research Site
  - Cagayan De Oro City, Philippines, 9000
    - Withdrawn
    - Research Site
  - Cebu, Philippines, 6000
    - Recruiting
    - Research Site
  - Cebu City, Philippines, 6000
    - Recruiting
    - Research Site
  - Iloilo City, Philippines, 5000
    - Recruiting
    - Research Site
  - Muntinlupa City, Philippines, 1780
    - Recruiting
    - Research Site
  - Quezon City, Philippines, 1101
    - Recruiting
    - Research Site
  - Quezon City, Philippines, 1112
    - Recruiting
    - Research Site
  - San Juan, Philippines, 1500
    - Recruiting
    - Research Site
Poland
- - Białystok, Poland, 15-027
    - Recruiting
    - Research Site
  - Bydgoszcz, Poland, 85-796
    - Recruiting
    - Research Site
  - Skórzewo, Poland, 60-185
    - Recruiting
    - Research Site
  - Tomaszów Mazowiecki, Poland, 97-200
    - Withdrawn
    - Research Site
  - Warszawa, Poland, 02-781
    - Recruiting
    - Research Site
  - Wroclaw, Poland, 53-413
    - Recruiting
    - Research Site
  - Łódź, Poland, 93-338
    - Recruiting
    - Research Site
Singapore
- - Bukit Merah, Singapore, 169610
    - Recruiting
    - Research Site
  - Singapore, Singapore, 308433
    - Recruiting
    - Research Site
  - Singapore, Singapore, 119074
    - Recruiting
    - Research Site
  - Singapore, Singapore, 329563
    - Recruiting
    - Research Site
South Africa
- - Amanzimtoti, South Africa, 4126
    - Withdrawn
    - Research Site
  - Cape Town, South Africa, 7570
    - Recruiting
    - Research Site
  - Johannesburg, South Africa, 2196
    - Recruiting
    - Research Site
  - Parktown, South Africa, 2193
    - Not yet recruiting
    - Research Site
  - Pretoria, South Africa, 0081
    - Recruiting
    - Research Site
  - Pretoria, South Africa, 0002
    - Recruiting
    - Research Site
  - Richards Bay, South Africa, 3900
    - Recruiting
    - Research Site
  - Soweto, South Africa, 2013
    - Recruiting
    - Research Site
Spain
- - Barcelona, Spain, 08028
    - Recruiting
    - Research Site
  - Barcelona, Spain, 8035
    - Recruiting
    - Research Site
  - Granada, Spain, 18016
    - Recruiting
    - Research Site
  - L'Hospitalet de Llobregat, Spain, 08908
    - Recruiting
    - Research Site
  - Madrid, Spain, 28007
    - Recruiting
    - Research Site
  - Madrid, Spain, 28046
    - Recruiting
    - Research Site
  - Madrid, Spain, 28034
    - Suspended
    - Research Site
  - Majadahonda, Spain, 28222
    - Recruiting
    - Research Site
  - Málaga, Spain, 29010
    - Recruiting
    - Research Site
  - Santiago de Compostela, Spain, 15706
    - Recruiting
    - Research Site
  - Sevilla, Spain, 41013
    - Recruiting
    - Research Site
Taiwan
- - Hsinchu, Taiwan, 300
    - Recruiting
    - Research Site
  - Taichung, Taiwan, 40447
    - Recruiting
    - Research Site
  - Taichung, Taiwan, 40705
    - Recruiting
    - Research Site
  - Tainan, Taiwan, 710
    - Recruiting
    - Research Site
  - Tainan City, Taiwan, 70403
    - Recruiting
    - Research Site
  - Taipei, Taiwan, 10002
    - Recruiting
    - Research Site
  - Taipei City, Taiwan, 11217
    - Recruiting
    - Research Site
  - Taoyuan, Taiwan, 00333
    - Recruiting
    - Research Site
Thailand
- - Bangkok, Thailand, 10210
    - Recruiting
    - Research Site
  - Bangkok, Thailand, 10400
    - Recruiting
    - Research Site
  - Bangkok, Thailand, 10330
    - Recruiting
    - Research Site
  - Chiang Mai, Thailand, 50200
    - Recruiting
    - Research Site
  - Dusit, Thailand, 10300
    - Recruiting
    - Research Site
  - Hat Yai, Thailand, 90110
    - Recruiting
    - Research Site
  - Khon Kaen, Thailand, 40002
    - Recruiting
    - Research Site
Turkey
- - Ankara, Turkey, 06340
    - Recruiting
    - Research Site
  - Ankara, Turkey, 06520
    - Recruiting
    - Research Site
  - Diyarbakir, Turkey, 21280
    - Recruiting
    - Research Site
  - Istanbul, Turkey, 34662
    - Recruiting
    - Research Site
  - Izmir, Turkey, 35575
    - Recruiting
    - Research Site
  - Izmir, Turkey, 35100
    - Withdrawn
    - Research Site
  - Konya, Turkey, 42080
    - Recruiting
    - Research Site
  - Malatya, Turkey, 44280
    - Recruiting
    - Research Site
United Kingdom
- - Bristol, United Kingdom, BS2 8ED
    - Recruiting
    - Research Site
  - Cardiff, United Kingdom, CF14 2TL
    - Recruiting
    - Research Site
  - Edinburgh, United Kingdom, EH4 2XU
    - Recruiting
    - Research Site
  - Inverness, United Kingdom, IV2 3UJ
    - Withdrawn
    - Research Site
  - London, United Kingdom, EC1A 7BE
    - Recruiting
    - Research Site
  - London, United Kingdom, SE1 9RT
    - Recruiting
    - Research Site
  - London, United Kingdom, SW17 0QT
    - Recruiting
    - Research Site
  - Newcastle upon Tyne, United Kingdom, NE7 7AF
    - Recruiting
    - Research Site
  - Northampton, United Kingdom, NN1 5BD
    - Recruiting
    - Research Site
  - Nottingham, United Kingdom, NG5 1PB
    - Recruiting
    - Research Site
  - Swansea, United Kingdom, SA2 8QA
    - Recruiting
    - Research Site
  - Warwick, United Kingdom, CV34 5BW
    - Recruiting
    - Research Site
United States
- California
  - Duarte, California, United States, 91010
    - Recruiting
    - Research Site
  - Los Angeles, California, United States, 90017
    - Recruiting
    - Research Site
  - Newport Beach, California, United States, 92660
    - Recruiting
    - Research Site
  - San Francisco, California, United States, 94143
    - Recruiting
    - Research Site
  - Santa Rosa, California, United States, 95405
    - Withdrawn
    - Research Site
  - Stanford, California, United States, 94305
    - Withdrawn
    - Research Site
- Colorado
  - Grand Junction, Colorado, United States, 81501
    - Recruiting
    - Research Site
  - Longmont, Colorado, United States, 80504
    - Recruiting
    - Research Site
- Connecticut
  - New Haven, Connecticut, United States, 06510
    - Recruiting
    - Research Site
- District of Columbia
  - Washington, District of Columbia, United States, 20010
    - Recruiting
    - Research Site
- Florida
  - Miami, Florida, United States, 33176
    - Recruiting
    - Research Site
  - Miami, Florida, United States, 33170
    - Recruiting
    - Research Site
- Georgia
  - Atlanta, Georgia, United States, 30322
    - Recruiting
    - Research Site
- Kentucky
  - Lexington, Kentucky, United States, 40503
    - Recruiting
    - Research Site
  - Louisville, Kentucky, United States, 40207
    - Recruiting
    - Research Site
- Louisiana
  - Baton Rouge, Louisiana, United States, 70808
    - Recruiting
    - Research Site
  - Shreveport, Louisiana, United States, 71105
    - Recruiting
    - Research Site
- Maryland
  - Baltimore, Maryland, United States, 21201
    - Recruiting
    - Research Site
- Massachusetts
  - Boston, Massachusetts, United States, 02111
    - Recruiting
    - Research Site
- Michigan
  - Detroit, Michigan, United States, 48201
    - Recruiting
    - Research Site
- Missouri
  - Saint Louis, Missouri, United States, 63141
    - Not yet recruiting
    - Research Site
- New Jersey
  - Florham Park, New Jersey, United States, 07932
    - Recruiting
    - Research Site
  - Hackensack, New Jersey, United States, 07601
    - Recruiting
    - Research Site
  - Paramus, New Jersey, United States, 07652
    - Recruiting
    - Research Site
- New Mexico
  - Albuquerque, New Mexico, United States, 87109
    - Recruiting
    - Research Site
- New York
  - New York, New York, United States, 10065
    - Recruiting
    - Research Site
  - New York, New York, United States, 10065
    - Not yet recruiting
    - Research Site
  - Syracuse, New York, United States, 13210
    - Withdrawn
    - Research Site
  - Westbury, New York, United States, 11590
    - Recruiting
    - Research Site
- North Carolina
  - Charlotte, North Carolina, United States, 28204
    - Recruiting
    - Research Site
  - Wilmington, North Carolina, United States, 28403
    - Not yet recruiting
    - Research Site
  - Winston-Salem, North Carolina, United States, 27103
    - Recruiting
    - Research Site
- Ohio
  - Columbus, Ohio, United States, 43210
    - Withdrawn
    - Research Site
- Rhode Island
  - Providence, Rhode Island, United States, 02903
    - Recruiting
    - Research Site
- South Dakota
  - Sioux Falls, South Dakota, United States, 57105
    - Recruiting
    - Research Site
- Tennessee
  - Memphis, Tennessee, United States, 38120
    - Recruiting
    - Research Site
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Research Site
- Texas
  - Austin, Texas, United States, 78731
    - Recruiting
    - Research Site
  - Fort Worth, Texas, United States, 76104
    - Recruiting
    - Research Site
  - Houston, Texas, United States, 77030
    - Recruiting
    - Research Site
  - Kingwood, Texas, United States, 77339
    - Recruiting
    - Research Site
  - San Antonio, Texas, United States, 78240
    - Recruiting
    - Research Site
  - Spring, Texas, United States, 77380
    - Recruiting
    - Research Site
- Virginia
  - Charlottesville, Virginia, United States, 22908
    - Recruiting
    - Research Site
  - Midlothian, Virginia, United States, 23114
    - Recruiting
    - Research Site
  - Norfolk, Virginia, United States, 23502
    - Recruiting
    - Research Site
- Washington
  - Spokane Valley, Washington, United States, 99216
    - Recruiting
    - Research Site
- West Virginia
  - Morgantown, West Virginia, United States, 26506
    - Recruiting
    - Research Site
- Wisconsin
  - Madison, Wisconsin, United States, 53792
    - Recruiting
    - Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Age

Participant must be ≥ 18 years at the time of screening. Type of Participant and Disease Characteristics
Histologically or cytologically documented locally recurrent inoperable TNBC, which cannot be treated with curative intent, or metastatic TNBC. TNBC is defined as:
- Negative for ER with < 1% of tumour cells positive for ER on IHC.
- Negative for progesterone receptor with < 1% of tumour cells positive for progesterone receptor on IHC.
- Negative for HER2 with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridisation per the ASCO-CAP HER2 guideline
No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
Not a candidate for PD-1/PD-L1 inhibitor therapy, defined as:
- Participants whose tumours are PD-L1-negative, or
- Participants whose tumours are PD-L1-positive and have:
  1. relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer,
  2. comorbidities precluding PD-1/PD-L1 inhibitor therapy, or
  3. no regulatory access to pembrolizumab [participant's country does not have regulatory approval at the time of screening]).
At least 1 measurable lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and is suitable for accurate repeated measurements.
ECOG PS 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin), based on DFI and prior taxane exposure, per investigator assessment.
Has had an adequate treatment washout period before Cycle 1 Day 1, defined as:
- Major surgery: ≥ 3 weeks.
- Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
- Corticosteroid therapy for central nervous system metastatic disease: > 3 days.
- Anti cancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
- Nitrosoureas or mitomycin C: ≥ 6 weeks.
- Antibody-based anti cancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
- Immunotherapy (non-antibody-based therapy), retinoid therapy: ≥ 2 weeks or 5 times the terminal elimination half-life of the agent, whichever is longer.
- Chloroquine/hydroxychloroquine: > 14 days.
Written confirmation of tumour sample needs to be available prior to enrolment and tumour samples should be available prior to randomisation. All participants must have a FFPE metastatic (excluding bone) or locally recurrent inoperable tumour sample (block preferred, or a minimum of 20 freshly cut slides) available, collected ≤ 3 months prior to screening. If neither an adequate FFPE block nor the minimum of 20 slides are available from the most recent biopsy, or if a biopsy is not feasible for safety reasons, and this is clearly documented, an archival tumour specimen obtained before the diagnosis of locally recurrent inoperable or metastatic breast cancer may be submitted, pending approval by the Global Study Team.
Participants with a history of previously treated neoplastic spinal cord compression or asymptomatic, stable brain metastases, who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they are no longer symptomatic and have recovered from acute toxic effects of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and Cycle 1 Day 1. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for central nervous system metastatic disease and Cycle 1 Day 1.
Adequate organ and bone marrow function within 7 days before randomisation as follows:
- Haemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
- Absolute neutrophil count ≥ 1.5 × 10^9/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment).
- Platelet count ≥ 100 × 10^9/L (platelet transfusion is not allowed within 1 week prior to screening assessment).
- Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) or < 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia).
- Except in the setting of HBV, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN for AST/ALT (< 5 × ULN in participants with liver metastases). See Exclusion Criterion 5 for requirements in the setting of HBV.
- Calculated CrCL ≥ 30 mL/minute as determined by Cockcroft Gault
Minimum life expectancy of 12 weeks.
Sex
Male or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Reproduction
Negative pregnancy test (serum) for women of childbearing potential.
Female participants must be at least 1 year post-menopausal, surgically sterile, or using at least 1 highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.) Women of childbearing potential who are sexually active with a non sterilised male partner must agree to use at least 1 highly effective method of birth control. They should have been stable on their chosen method of birth control for a minimum of 3 months before Cycle 1 Day 1 and continue for at least 7 months after the last dose. Female participants must refrain from egg cell donation or retrieval for their own use, and breastfeeding from enrolment throughout the study and for at least 7 months after the last dose of study drug. Any non sterilised male partner of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.
Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or use an acceptable method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 6 months after the last dose of study intervention), in addition to the female partner using a highly effective contraceptive method, to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Preservation of sperm should be considered prior to randomisation. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice, if this is the preferred usual lifestyle of the participant. Periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Informed Consent
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.

Exclusion Criteria:

Medical Conditions

As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, uncontrolled hypertension, history of allogeneic organ transplant, and active bleeding diseases, ongoing or active infection, or significant cardiac or psychological conditions), and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence (per investigator assessment). Exceptions include adequately resected non-melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease.
Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss).
Uncontrolled infection requiring IV antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
Known active or uncontrolled hepatitis B or C virus infection.
Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, cluster of differentiation (CD)4+ count > 350 cells/mm3, no history of an acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications.
Uncontrolled or significant cardiac disease including:
- Myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1
- Congestive heart failure (New York Heart Association Class II to IV), or
- Uncontrolled or significant cardiac arrhythmia, or
- Uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
Resting ECG with clinically abnormal findings.
Uncontrolled hypercalcaemia: > 1.5 mmol/L (> 6 mg/dL) ionised calcium, or serum calcium (uncorrected for albumin) > 3 mmol/L (> 12 mg/dL), or corrected serum calcium > ULN, or clinically significant (symptomatic) hypercalcaemia.
History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Has severe pulmonary function compromise.
Leptomeningeal carcinomatosis.
Clinically significant corneal disease.
Known active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
Prior/Concomitant Therapy
Prior exposure to:
- Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
- TROP2-targeted therapy
- Prior treatment with same ICC agent
- Chloroquine/hydroxychloroquine without an adequate treatment washout period of > 14 days prior to randomisation.
Any concurrent anti cancer treatment.
Concurrent use of systemic hormone replacement therapy (HRT; eg, oestrogen and progesterone). However, concurrent use of hormones for other non-cancer-related conditions (eg, insulin for diabetes or levothyroxine for hypothyroidism) is acceptable.
Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.
Concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications except for managing AEs (inhaled steroids or intra articular steroid injections are permitted in this study).
Prior/Concurrent Clinical Study Experience
Previous randomisation in the present study.
Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention (unless the safety profile is known prior to randomisation), randomisation into a prior T-DXd or Dato DXd study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study.
Participants with a known history of severe hypersensitivity reactions to either the drug or any excipients (including but not limited to polysorbate 80) of Dato-DXd or ICC.
Known history of severe hypersensitivity reactions to other monoclonal antibodies.
Other Exclusions
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
Currently pregnant (confirmed with positive pregnancy test) or breast feeding or planning to become pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: None (Open Label)

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dato-DXd Arm 1: Dato-DXd	Drug: Dato-DXd Experimental drug. Provided in 100mg vials. IV infusion. Other Names: Datopotamab deruxtecan (Dato-DXd, DS-1062a)
Active Comparator: Investigator's Choice of Chemotherapy (ICC) Arm 2: If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI > 12 months, paclitaxel or nab-paclitaxel If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin.	Drug: Paclitaxel IV Infusion. Active comparator Drug: Nab-paclitaxel IV infusion. Active comparator Drug: Carboplatin IV infusion. Active comparator Drug: Capecitabine Tablet. Oral route of administration. Active comparator Drug: Eribulin mesylate IV infusion. Active comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS) Time Frame: From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)	PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the hazard ratio [HR] of PFS.	From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)
Overall Survival (OS) Time Frame: From randomisation until the date of death due to any cause (approximately 42 months)	OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, by treatment group as randomised. The measure of interest is the hazard ratio [HR] of OS.	From randomisation until the date of death due to any cause (approximately 42 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) Time Frame: From randomisation up until progression (anticipated to be up to 26 months)	ORR is defined as the proportion of participants who have a confirmed CR or PR, as determined by BICR/investigator assessment, per RECIST 1.1. The analysis will include all randomised participants, by treatment group as randomised. Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent anti-cancer therapy, and then respond will not be included as responders in the ORR. The measure of interest is the odds ratio of the ORR.	From randomisation up until progression (anticipated to be up to 26 months)
Duration of Response (DoR) Time Frame: From the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 26 months)	DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. The analysis will include all randomised participants as randomised who have a confirmed response, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. The measure of interest is the median of DoR,	From the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 26 months)
Progression-Free Survival (PFS) by Investigator assessment Time Frame: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 26 months)	PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. The measure of interest is the hazard ratio [HR] of PFS.	From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 26 months)
Time to deterioration (TTD) in pain in participants treated with Dato DXd compared with ICC Time Frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)	TTD in pain as measured by the pain scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio [HR] of TTD in pain.	From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)
Time to deterioration (TTD) in physical functioning in participants treated with Dato DXd compared with ICC Time Frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)	TTD in physical functioning as measured by the physical functioning scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio [HR] of TTD in physical functioning.	From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato DXd compared to ICC Time Frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)	TTD in breast symptoms as measured by the breast symptoms scale from EORTC IL116 TTD in arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio [HR] of TTD in breast symptoms/arm symptoms.	From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato DXd compared with ICC Time Frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)	TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio [HR] of TTD in GHS/QoL.	From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)
Time to First Subsequent Therapy (TFST) Time Frame: From randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 26 months)	TFST is defined as the time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of progression status. The measure of interest is the hazard ratio [HR] of TFST.	From randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 26 months)
Time to Second Subsequent Therapy (TSST) Time Frame: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 26 months)	TSST is defined as the time from randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of progression status on study treatment or first subsequent treatment. The measure of interest is the hazard ratio [HR] of TSST.	From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 26 months)
Progression Free Survival 2 (PFS2) Time Frame: From randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 26 months)	PFS2 will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice. The analysis will include all randomised participants as randomised regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits. The measure of interest is the hazard ratio [HR] of PFS2.	From randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 26 months)
Pharmacokinetics of Dato-DXd Time Frame: From first dose to end of treatment (anticipated to be up to 26 months)	Concentration of Dato DXd, total anti-TROP2 antibody, and MAAA-1181a in plasma.	From first dose to end of treatment (anticipated to be up to 26 months)
Immunogenicity of Dato-DXd Time Frame: From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)	Presence of ADAs for Dato-DXd (confirmatory results: positive or negative, titres).	From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)
Safety of Dato-DXd Time Frame: From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)	Safety will be evaluated in terms of AEs (graded by CTCAE version 5.0)	From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)
Disease Control Rate (DCR) Time Frame: At least 11 weeks after randomization to 23 months	DCR at 12 weeks is defined as the percentage of participants who have a confirmed CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/investigator assessment and derived from the raw tumour data for at least 11 weeks after randomisation. The analysis will include all randomised participants by treatment group as randomised. Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of DCR, regardless of whether the participant withdraws from therapy. Participants who receive a subsequent anticancer therapy prior to Week 11 will not be considered to have disease control in the analysis. The measure of interest is the odds ratio of the DCR.	At least 11 weeks after randomization to 23 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Collaborators

Daiichi Sankyo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 16, 2022

Primary Completion (Estimated)

December 3, 2025

Study Completion (Estimated)

December 3, 2025

Study Registration Dates

First Submitted

April 19, 2022

First Submitted That Met QC Criteria

May 10, 2022

First Posted (Actual)

May 16, 2022

Study Record Updates

Last Update Posted (Actual)

March 21, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

D926PC00001
2021-005223-21 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Supporting Information Type

STUDY_PROTOCOL
SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Northwestern University
Eisai Inc.

Unknown

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Endoscopic Breast Surgery in Treating Patients With Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University of Washington

Terminated

Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIc

United States
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
University of Southern California
National Cancer Institute (NCI)

Terminated

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Susan G. Komen Breast Cancer Foundation

Completed

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

Clinical Trials on Dato-DXd

Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Carcinoma, Non-Small-Cell Lung | Triple Negative Breast Cancer

China
Sarah Sammons, MD
Daiichi Sankyo

Recruiting

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Breast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast Cancer

United States
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer

Belgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Estimated)

Phase

Contacts and Locations

Study Contact

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Estimated)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

IPD Sharing Time Frame

IPD Sharing Access Criteria

IPD Sharing Supporting Information Type

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Breast Cancer

Clinical Trials on Dato-DXd

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations